Article
Neoadjuvant Chemotherapy plus Bevacizumab Combined with Total Mesorectal Excision in Treating Locally Advanced Rectal Cancer Patients with BRAF Mutation: Clinical Benefit and Safety.
Computational and mathematical methods in medicine - 1 Jan 2021
Song Jintian, Wang Yi, Yu Hui, Zheng Liang, Cai Xiongchao, Chen Yigui
Abstract excerpt
OBJECTIVE: To investigate clinical benefit and safety of neoadjuvant chemotherapy (NAC) plus bevacizumab combined with total mesorectal excision (TME) in treating patients with BRAF-mutated locally advanced rectal cancer (LARC). METHODS: This study included LARC patients with BRAF mutation admitted to the Oncology Department of Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, between June 2013...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.